Search

Your search keyword '"Jha, Manish K."' showing total 478 results
Start Over Author "Jha, Manish K." Publication Year Range Last 10 years
478 results on '"Jha, Manish K."'

1. Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial

Author

Papakostas, George I., Trivedi, Madhukar H., Shelton, Richard C., Iosifescu, Dan V., Thase, Michael E., Jha, Manish K., Mathew, Sanjay J., DeBattista, Charles, Dokucu, Mehmet E., Brawman-Mintzer, Olga, Currier, Glenn W., McCall, William Vaughn, Modirrousta, Mandana, Macaluso, Matthew, Bystritsky, Alexander, Rodriguez, Fidel Vila, Nelson, Erik B., Yeung, Albert S., Feeney, Anna, MacGregor, Leslie C., Carmody, Thomas, and Fava, Maurizio

Published
2024
Full Text
View/download PDF

10. An electroencephalographic signature predicts antidepressant response in major depression

Author

Wu, Wei, Zhang, Yu, Jiang, Jing, Lucas, Molly V, Fonzo, Gregory A, Rolle, Camarin E, Cooper, Crystal, Chin-Fatt, Cherise, Krepel, Noralie, Cornelssen, Carena A, Wright, Rachael, Toll, Russell T, Trivedi, Hersh M, Monuszko, Karen, Caudle, Trevor L, Sarhadi, Kamron, Jha, Manish K, Trombello, Joseph M, Deckersbach, Thilo, Adams, Phil, McGrath, Patrick J, Weissman, Myrna M, Fava, Maurizio, Pizzagalli, Diego A, Arns, Martijn, Trivedi, Madhukar H, and Etkin, Amit

Subjects
Serious Mental Illness, Neurosciences, Mental Health, Major Depressive Disorder, Depression, Clinical Research, Brain Disorders, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Mental health, Good Health and Well Being, Antidepressive Agents, Depressive Disorder, Major, Double-Blind Method, Electroencephalography, Humans, Machine Learning, Membrane Potentials, Models, Neurological, Predictive Value of Tests, Prefrontal Cortex, Reproducibility of Results, Sertraline, Transcranial Magnetic Stimulation, Treatment Outcome
Abstract

Antidepressants are widely prescribed, but their efficacy relative to placebo is modest, in part because the clinical diagnosis of major depression encompasses biologically heterogeneous conditions. Here, we sought to identify a neurobiological signature of response to antidepressant treatment as compared to placebo. We designed a latent-space machine-learning algorithm tailored for resting-state electroencephalography (EEG) and applied it to data from the largest imaging-coupled, placebo-controlled antidepressant study (n = 309). Symptom improvement was robustly predicted in a manner both specific for the antidepressant sertraline (versus placebo) and generalizable across different study sites and EEG equipment. This sertraline-predictive EEG signature generalized to two depression samples, wherein it reflected general antidepressant medication responsivity and related differentially to a repetitive transcranial magnetic stimulation treatment outcome. Furthermore, we found that the sertraline resting-state EEG signature indexed prefrontal neural responsivity, as measured by concurrent transcranial magnetic stimulation and EEG. Our findings advance the neurobiological understanding of antidepressant treatment through an EEG-tailored computational model and provide a clinical avenue for personalized treatment of depression.

Published
2020

11. Brain regulation of emotional conflict predicts antidepressant treatment response for depression

Author

Fonzo, Gregory A, Etkin, Amit, Zhang, Yu, Wu, Wei, Cooper, Crystal, Chin-Fatt, Cherise, Jha, Manish K, Trombello, Joseph, Deckersbach, Thilo, Adams, Phil, McInnis, Melvin, McGrath, Patrick J, Weissman, Myrna M, Fava, Maurizio, and Trivedi, Madhukar H

Subjects
Biological Psychology, Biomedical and Clinical Sciences, Clinical Sciences, Psychology, Clinical Trials and Supportive Activities, Neurosciences, Brain Disorders, Clinical Research, Mind and Body, Behavioral and Social Science, Mental Health, Depression, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Mental health, Good Health and Well Being, Antidepressive Agents, Antidepressive Agents, Second-Generation, Brain, Clinical Trials as Topic, Depressive Disorder, Major, Humans, Magnetic Resonance Imaging, Neuroimaging, Treatment Outcome, Biomedical and clinical sciences, Health sciences
Abstract

The efficacy of antidepressant treatment for depression is controversial due to the only modest superiority demonstrated over placebo. However, neurobiological heterogeneity within depression may limit overall antidepressant efficacy. We sought to identify a neurobiological phenotype responsive to antidepressant treatment by testing pretreatment brain activation during response to, and regulation of, emotional conflict as a moderator of the clinical benefit of the antidepressant sertraline versus placebo. Using neuroimaging data from a large randomized controlled trial, we found widespread moderation of clinical benefits by brain activity during regulation of emotional conflict, in which greater downregulation of conflict-responsive regions predicted better sertraline outcomes. Treatment-predictive machine learning using brain metrics outperformed a model trained on clinical and demographic variables. Our findings demonstrate that antidepressant response is predicted by brain activity underlying a key self-regulatory emotional capacity. Leveraging brain-based measures in psychiatry will forge a path toward better treatment personalization, refined mechanistic insights and improved outcomes.

Published
2019

17. Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial

Author

Trombello, Joseph M., Cooper, Crystal M., Fatt, Cherise Chin, Grannemann, Bruce D., Carmody, Thomas J., Jha, Manish K., Mayes, Taryn L., Greer, Tracy L., Yezhuvath, Uma, Aslan, Sina, Pizzagalli, Diego A., Weissman, Myrna M., Webb, Christian A., Dillon, Daniel G., McGrath, Patrick J., Fava, Maurizio, Parsey, Ramin V., McInnis, Melvin G., Etkin, Amit, and Trivedi, Madhukar H.

Published
2022
Full Text
View/download PDF

20. Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT‐2 trial.

Author

Li, Michael J., Chau, Brendon, Belin, Thomas, Carmody, Thomas, Jha, Manish K., Marino, Elise N., Trivedi, Madhukar, and Shoptaw, Steven J.

Subjects
COMBINATION drug therapy, SUBSTANCE abuse, METHAMPHETAMINE, SECONDARY analysis, RESEARCH funding, DESCRIPTIVE statistics, TREATMENT effectiveness, DRUG use testing, BUPROPION, DRUG efficacy, CONFIDENCE intervals, NALTREXONE
Abstract

Background and aims: A 12‐week placebo‐controlled, sequential parallel Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder (ADAPT‐2) trial evaluated the effects of extended‐release injectable naltrexone plus extended‐release oral bupropion (NTX + BUPN) on methamphetamine (MA) use over two stages. This study reports on the previously unpublished stage 2 MA use in participants randomized at stage 1 to receive NTX + BUPN through both stages compared with those assigned to placebo. Design: This is a secondary analysis of the US National Institute on Drug Abuse (NIDA) ADAPT‐2 network trial. Setting: The parent ADAPT‐2 trial was carried out across multiple NIDA Clinical Trials Network (CTN) sites in the United States. Participants: This analysis includes 403 people with MA use disorder who participated in the ADAPT‐2 CTN trial. Intervention and comparator: NTX + BUPN was compared with placebo over the course of the trial. Measurement MA use was measured by urine drug screens conducted twice weekly for 12 weeks, then once in week 13 and once in week 16 post‐treatment follow‐up. Findings Participants on NTX + BUPN in stage 1 showed an additional 9.2% increase [95% confidence interval (CI), 0.09%–17.9%, P = 0.038] during stage 2 in their probability of testing negative for MA, with a total increase of 27.1% (95% CI, 13.2%–41.1%, P < 0.001) over the full 12 weeks of treatment. In contrast, participants on placebo in both stages increased in probability of testing MA‐negative by a total of 11.4% (95% CI, 4.1%–18.6%, P = 0.002) over all 12 weeks. The 12‐week increase among participants on NTX + BUPN was significantly greater—by 15.8% (95% CI, 4.5%–27.0%, P = 0.006)—than the increase among those on placebo. Conclusion: For people with methamphetamine (MA) use disorder receiving treatment with extended‐release injectable naltrexone plus extended‐release oral bupropion (NTX + BUPN), continued treatment with NTX + BUPN after 6 weeks is associated with additional reductions in MA use up to 12 weeks. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Pharmacogenomics and Biomarkers of Depression

Author

Jha, Manish K., Trivedi, Madhukar H., Barrett, James E., Editor-in-Chief, Flockerzi, Veit, Editorial Board Member, Frohman, Michael A., Editorial Board Member, Geppetti, Pierangelo, Editorial Board Member, Hofmann, Franz B., Editorial Board Member, Michel, Martin C., Editorial Board Member, Page, Clive P., Editorial Board Member, Rosenthal, Walter, Editorial Board Member, Wang, KeWei, Editorial Board Member, Macaluso, Matthew, editor, and Preskorn, Sheldon H., editor

Published
2019
Full Text
View/download PDF

34. Comprehensive phenotyping of depression disease trajectory and risk: Rationale and design of Texas Resilience Against Depression study (T-RAD)

Author

Trivedi, Madhukar H., Chin Fatt, Cherise R., Jha, Manish K., Cooper, Crystal M., Trombello, Joseph M., Mason, Brittany L., Hughes, Jennifer, Gadad, Bharathi S., Czysz, Andrew H., Toll, Russell T., Fuller, Anne K., Sethuram, Sangita, Mayes, Taryn L., Minhajuddin, Abu, Carmody, Thomas, and Greer, Tracy L.

Published
2020
Full Text
View/download PDF

38. Features of immunometabolic depression as predictors of antidepressant treatment outcomes: pooled analysis of four clinical trials

Author

Vreijling, Sarah R., primary, Chin Fatt, Cherise R., additional, Williams, Leanne M., additional, Schatzberg, Alan F., additional, Usherwood, Tim, additional, Nemeroff, Charles B., additional, Rush, A. John, additional, Uher, Rudolf, additional, Aitchison, Katherine J., additional, Köhler-Forsberg, Ole, additional, Rietschel, Marcella, additional, Trivedi, Madhukar H., additional, Jha, Manish K., additional, Penninx, Brenda W. J. H., additional, Beekman, Aartjan T. F., additional, Jansen, Rick, additional, and Lamers, Femke, additional

Published
2023
Full Text
View/download PDF

40. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)

Author

Fava, Maurizio, Freeman, Marlene P., Flynn, Martina, Judge, Heidi, Hoeppner, Bettina B., Cusin, Cristina, Ionescu, Dawn F., Mathew, Sanjay J., Chang, Lee C., Iosifescu, Dan V., Murrough, James, Debattista, Charles, Schatzberg, Alan F., Trivedi, Madhukar H., Jha, Manish K, Sanacora, Gerard, Wilkinson, Samuel T., and Papakostas, George I.

Published
2020
Full Text
View/download PDF

45. Features of immunometabolic depression as predictors of antidepressant treatment outcomes: pooled analysis of four clinical trials.

Author

Vreijling, Sarah R., Chin Fatt, Cherise R., Williams, Leanne M., Schatzberg, Alan F., Usherwood, Tim, Nemeroff, Charles B., Rush, A. John, Uher, Rudolf, Aitchison, Katherine J., Köhler-Forsberg, Ole, Rietschel, Marcella, Trivedi, Madhukar H., Jha, Manish K., Penninx, Brenda W. J. H., Beekman, Aartjan T. F., Jansen, Rick, and Lamers, Femke

Subjects
SEROTONIN uptake inhibitors, TREATMENT effectiveness, ANTIDEPRESSANTS, CLINICAL trials, MENTAL depression
Abstract

Background: Profiling patients on a proposed 'immunometabolic depression' (IMD) dimension, described as a cluster of atypical depressive symptoms related to energy regulation and immunometabolic dysregulations, may optimise personalised treatment. Aims: To test the hypothesis that baseline IMD features predict poorer treatment outcomes with antidepressants. Method: Data on 2551 individuals with depression across the iSPOT-D (n = 967), CO-MED (n = 665), GENDEP (n = 773) and EMBARC (n = 146) clinical trials were used. Predictors included baseline severity of atypical energy-related symptoms (AES), body mass index (BMI) and C-reactive protein levels (CRP, three trials only) separately and aggregated into an IMD index. Mixed models on the primary outcome (change in depressive symptom severity) and logistic regressions on secondary outcomes (response and remission) were conducted for the individual trial data-sets and pooled using random-effects meta-analyses. Results: Although AES severity and BMI did not predict changes in depressive symptom severity, higher baseline CRP predicted smaller reductions in depressive symptoms (n = 376, βpooled = 0.06, P = 0.049, 95% CI 0.0001–0.12, I 2 = 3.61%); this was also found for an IMD index combining these features (n = 372, βpooled = 0.12, s.e. = 0.12, P = 0.031, 95% CI 0.01–0.22, I 2 = 23.91%), with a higher – but still small – effect size compared with CRP. Confining analyses to selective serotonin reuptake inhibitor users indicated larger effects of CRP (βpooled = 0.16) and the IMD index (βpooled = 0.20). Baseline IMD features, both separately and combined, did not predict response or remission. Conclusions: Depressive symptoms of people with more IMD features improved less when treated with antidepressants. However, clinical relevance is limited owing to small effect sizes in inconsistent associations. Whether these patients would benefit more from treatments targeting immunometabolic pathways remains to be investigated. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results